Non-Hodgkin Lymphoma | Specialty

Combination Therapy the Future for Mantle Cell Lymphoma

September 24th 2015

The heterogeneity of mantle cell lymphoma will require new combination strategies to improve outcomes.

Progress Toward Reducing Failure in Follicular Lymphoma

September 24th 2015

Lack of improvement in failure-free survival for patients with follicular lymphoma has fueled interest in new treatment strategies that might offer promise of better outcomes.

High-Risk Follicular Lymphoma Subgroup Identified

August 24th 2015

Patients with follicular lymphoma progressing within 2 years on first-line R-CHOP have a 5-year overall survival rate of only 50%, compared with 90% in longer responders.

Obinutuzumab's Benefit in iNHL Unclear After GAUSS Results Published

August 24th 2015

The anti-CD20 agent obinutuzumab improved overall response and had acceptable toxicity compared with rituximab in patients with relapsed indolent non-Hodgkin Lymphoma, according to the final results from the GAUSS study.

Dr. Leonard on Ibrutinib Combined With Chemotherapy in Follicular Lymphoma

August 20th 2015

John P. Leonard, MD, medical oncology, NewYork-Presbyterian Hospital/Weill Cornell Medical Center, discusses the phase III SELENE study, which is examining the addition of ibrutinib to either R-CHOP or bendamustine plus rituximab for the treatment of patients with follicular lymphoma.

Ibrutinib Induces Impressive Response in DLBCL Subtype

July 30th 2015

Ibrutinib had an overall response rate of 37% in patients with activated B-cell-like diffuse large B-cell lymphoma.

Gender Disparities and Other DLBCL Developments

July 28th 2015

Tahir Latif, MD, discusses results of a recent study which found that men may have a lower rate of survival among patients with diffuse large B-cell lymphoma.

Dr. Bruce D. Cheson on Obinutuzumab/ Bendamustine Survival Benefit in iNHL

July 23rd 2015

Bruce D. Cheson, MD, Professor of Medicine, Head of Hematology, Deputy Chief, Division of Hematology/Oncology, Georgetown University Hospital, Lombardi Comprehensive Cancer Center, discusses the phase III GADOLIN study, which looks at the anti-CD20 agent obinutuzumab (Gazyva) and bendamustine compared with bendamustine alone in patients with relapsed indolent non-Hodgkin lymphoma (iNHL).

Non-Intensive Treatments for Mantle Cell Lymphoma

June 30th 2015

Treatments for Relapsed Mantle Cell Lymphoma

June 30th 2015

Upfront Treatments for Mantle Cell Lymphoma

June 30th 2015

Treating Relapsed Diffuse Large B-Cell Lymphoma

June 30th 2015

Diffuse Large B-Cell Lymphoma Treatment Regimens

June 30th 2015

Management of Refractory Follicular Lymphoma

June 30th 2015

Stem Cell Transplantation in Follicular Lymphoma

June 30th 2015

Frontline Treatments for Follicular Lymphoma

June 30th 2015

Ibrutinib in Waldenström's Macroglobulinemia

June 30th 2015

B-Cell Receptor Inhibitor Response Criteria in CLL

June 30th 2015

Emerging Strategies in CLL and Follicular Lymphoma

June 30th 2015

Ibrutinib-Associated Adverse Events

June 30th 2015